{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:53:14Z","timestamp":1761540794070},"reference-count":68,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,7,2]],"date-time":"2007-07-02T00:00:00Z","timestamp":1183334400000},"content-version":"vor","delay-in-days":1977,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Interven Cardiology"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:p>Glycoprotein (GP) IIb\/IIIa antagonists are a unique class of antiplatelet agents introduced for the management of patients undergoing percutaneous coronary intervention (PCI) and those presenting with unstable angina or non\u2010ST segment elevation (NSTE) myocardial infarction (MI), collectively recognized as acute coronary syndromes (ACS). Eptifibatide, abciximab, and tirofiban HCl are three GPIIb\/IIIa antagonists approved for use by the Food and Drug Administration. Of the three agents, eptifibatide is approved for use in both PCI and NSTE ACS patient populations, whereas abciximab is indicated for patients undergoing PCI, and tirofiban is approved for patients with NSTE A CS. Dose selection for the initial trials using the three parenteral antagonists was based on in vitro and ex vivo pharmacodynamic assays conducted under different blood collection and platelet function assay conditions. Recent comparative pharmacodynamics studies, which used newly defined and standardized assay conditions, indicate that the platelet aggregation inhibition achieved with these dosing regimens is variable. Therefore, the differences in clinical efficacy as evidenced in the more recent clinical studies (e.g., Enhanced Suppression of the Platelet Receptor GPIIb\/IIIa using Integrilin Therapy [ESPRIT], Global Use of Strategies to Open Occluded Coronary Arteries TV Acute Coronary Syndromes [GUSTO\u2010IV ACS], and Do Tirofiban HCl and ReoPro Give Similar Efficacy Outcomes Trial [TARGET]) may be related to the variable antiplatelet effects of the approved dose regimens.<\/jats:p>","DOI":"10.1111\/j.1540-8183.2002.tb01034.x","type":"journal-article","created":{"date-parts":[[2007,7,2]],"date-time":"2007-07-02T09:38:00Z","timestamp":1183369080000},"page":"45-60","source":"Crossref","is-referenced-by-count":29,"title":["The Pharmacodynamics of Parenteral Glycoprotein IIb\/IIIa Inhibitors"],"prefix":"10.1111","volume":"15","author":[{"given":"LISA K.","family":"JENNINGS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARY V.","family":"JACOSKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MELANIE McCABE","family":"WHITE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,7,2]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201233260406"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8183.1998.tb00145.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/09537109009005485"},{"key":"e_1_2_1_5_2","first-page":"923","article-title":"Platelet activation by fibrinolytic agents: A potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis","volume":"6","author":"Leopold JA","year":"1995","journal-title":"Coron Artery Dis"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111931"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"11366","DOI":"10.1016\/S0021-9258(17)39188-3","article-title":"Calcium regulation of the platelet membrane glycoprotein IIb\/IIIa complex","volume":"260","author":"Fitzgerald LA","year":"1985","journal-title":"J Biol Chem"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1016\/S0021-9258(17)44449-8","article-title":"Calcium cation regulation of glycoprotein IIb\/IIIa complex formation in platelet plasma membranes","volume":"258","author":"Fujimura K","year":"1983","journal-title":"J Biol Chem"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"10458","DOI":"10.1016\/S0021-9258(18)34040-7","article-title":"Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium\u2010dependent glycoprotein IIb\u2010III complex","volume":"257","author":"Jennings LK","year":"1982","journal-title":"J Biol Chem"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V58.2.268.268","article-title":"The formation of Ca++\u2010dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed Immunoelectrophoresis","volume":"58","author":"Kunicki TJ","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood.V71.4.831.831","article-title":"The platelet membrane glycoprotein IIb\/IIIa complex","volume":"71","author":"Phillips DR","year":"1988","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00572-9"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506083322306"},{"key":"e_1_2_1_14_2","first-page":"117","article-title":"Cellular adhesion: GPIIb\/IIIa as a prototype adhesion receptor","volume":"9","author":"Plow EF","year":"1989","journal-title":"Prog Hemost Thromb"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.22.10729"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00303a028"},{"key":"e_1_2_1_17_2","first-page":"291","volume-title":"New Therapeutic Agents in Thrombosis and Thrombolysis","author":"Jordan RE","year":"1997"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00391-6"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.17.3.528"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00417-2"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80616-X"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448040-00007"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018779116791"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008887708104"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(99)70075-X"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88273-9"},{"key":"e_1_2_1_27_2","first-page":"355","volume-title":"New Therapeutic Agents in Thrombosis and Thrombolysis","author":"Deckelbaum LI","year":"1997"},{"key":"e_1_2_1_28_2","first-page":"1219","article-title":"Bleeding time: A guide to its diagnostic and clinical utility","volume":"113","author":"Burns ER","year":"1989","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90979-M"},{"key":"e_1_2_1_30_2","first-page":"28","volume-title":"Platelet Protocols","author":"White MM","year":"1999"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-199809090-00008"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116344"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1649196","article-title":"Platelet interaction with collagen fibrils in flowing blood, I: Reaction of human platelets with a\u2010chymotrypsin\u2010digested subendothelium","volume":"37","author":"Baumgartner HR","year":"1977","journal-title":"Thromb Haemostas"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(87)80330-1"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00500-5"},{"issue":"8","key":"e_1_2_1_36_2","first-page":"71i","article-title":"Platelet aggregation inhibition with single and double bolus regimens of eptifibatide (Integrilin). (Abstract)","volume":"86","author":"Choo J","year":"2000","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80345-2"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.4.1757"},{"key":"e_1_2_1_39_2","first-page":"624","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade with high\u2010dose INTEGRILIN\u2122 in coronary intervention: Results of the PRIDE study. (Abstract)","volume":"18","author":"Tcheng JE","year":"1997","journal-title":"Eur Heart J"},{"key":"e_1_2_1_40_2","unstructured":"JenningsLK WhiteMM SullivanCD et al.Direct pharmacodynamic comparison of parenteral glycoprotein IIb\/IIIa antagonists tirofiban eptifibatide and abciximab. (In preparation)."},{"issue":"8","key":"e_1_2_1_41_2","first-page":"69i","article-title":"Differential effects of citrate versus PPACK anticoagulants: Implications for comparing glycoprotein IIb\/IIIa inhibitors. (Abstract)","volume":"86","author":"Kukielka GL","year":"2000","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_42_2","first-page":"I","article-title":"Effect of anticoagulation and platelet agonist concentration on the inhibitory activities of GPIIb\/IIIa antagonists. (Abstract)","volume":"100","author":"Nannizzi\u2010Alaimo L","year":"1999","journal-title":"Circulation"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(90)90242-5"},{"key":"e_1_2_1_44_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1642390","article-title":"Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb\/IIIa inhibitors in animal models of platelet\u2010mediated thrombosis","volume":"71","author":"Collen D","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1488"},{"key":"e_1_2_1_46_2","first-page":"52a","article-title":"Eptifibatide pharmacokinetic\u2010pharmacodynamic relationship in coronary angioplasty patients: Results of the PRIDE study. Eur","volume":"19","author":"Kosoglou T","year":"1998","journal-title":"Heart J"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03400-0"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.152"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.4.860"},{"key":"e_1_2_1_51_2","first-page":"2572","article-title":"Assessing the optimal level of platelet inhibition with GPIIb\/IIIa inhibitors in patients undergoing coronary intervention: Rationale and design of the GOLD study","volume":"103","author":"Steinhubl SR","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00321-5"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.112489"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(98)70246-7"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2825(1998)12:4<191::AID-JCLA1>3.0.CO;2-B"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.17.2231"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.84.6.2463"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.80.6.1766"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.77.3.670"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.2.596"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404073301402"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc2901.093500"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1445"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442502"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018718914065"},{"key":"e_1_2_1_66_2","unstructured":"Jennings LK.Clinical trials of the parenteral GPIIb\/IIIa inhibitors: Considerations on the influence of dose selection on results. A CMA\u2010certified monograph.Health Science Center for Continuing Medical Education 2001."},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05060-1"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10172-0"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805213382102"}],"container-title":["Journal of Interventional Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-8183.2002.tb01034.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-8183.2002.tb01034.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:18:51Z","timestamp":1700306331000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-8183.2002.tb01034.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1111\/j.1540-8183.2002.tb01034.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-8183.2002.tb01034.x","archive":["Portico"],"relation":{},"ISSN":["0896-4327","1540-8183"],"issn-type":[{"value":"0896-4327","type":"print"},{"value":"1540-8183","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}